FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

This study is testing a new cell therapy called FT836, given alone or in combination with chemotherapy and/or antibody treatments, in people with advanced solid tumors that have progressed despite prior treatments. FT836 is a type of engineered immune cell designed to attack cancer. **You may be eligible if...** - You have advanced solid tumor cancer that cannot be cured and has progressed after at least one prior systemic treatment - Your cancer is measurable on scans - You are reasonably functional (ECOG 0 or 1) - You are willing to undergo biopsies during the study - Your blood counts, kidney, liver, and organ function are adequate **You may NOT be eligible if...** - You have significant untreated heart disease (heart failure, recent heart attack, arrhythmia, or low ejection fraction) - You have active brain metastases - You have a non-cancer brain or nervous system condition (like stroke or epilepsy) - You have received cancer treatments within 2 weeks or 5 drug half-lives before starting the study - You require long-term immune-suppressing steroids - You have had a prior severe immune-related reaction to cancer immunotherapy - You have significant peripheral neuropathy (nerve damage affecting daily function) Talk to your doctor to see if this trial is right for you.